Genmab A/S
GMAB
$24.65
$0.230.94%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 22.48% | 24.87% | 30.35% | 19.66% | 21.11% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 22.48% | 24.87% | 30.35% | 19.66% | 21.11% |
| Cost of Revenue | 121.17% | 164.89% | 337.23% | 676.55% | 2,661.37% |
| Gross Profit | 19.35% | 21.56% | 26.09% | 15.66% | 17.55% |
| SG&A Expenses | 11.96% | 10.80% | 16.98% | 9.77% | 18.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.55% | 22.05% | 30.04% | 26.88% | 36.17% |
| Operating Income | 35.21% | 30.85% | 31.01% | 7.10% | -2.14% |
| Income Before Tax | 31.50% | 27.84% | 61.25% | 26.56% | 35.14% |
| Income Tax Expenses | -41.57% | -21.60% | 3.18% | 79.72% | 77.56% |
| Earnings from Continuing Operations | 57.64% | 42.50% | 78.38% | 13.24% | 24.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 57.64% | 42.50% | 78.38% | 13.24% | 24.50% |
| EBIT | 35.21% | 30.85% | 31.01% | 7.10% | -2.14% |
| EBITDA | 35.47% | 31.39% | 31.69% | 7.46% | -1.74% |
| EPS Basic | 77.61% | 56.90% | 56.18% | -12.65% | -0.54% |
| Normalized Basic EPS | 44.67% | 43.87% | 44.22% | -3.07% | 4.25% |
| EPS Diluted | 77.81% | 57.03% | 56.29% | -12.51% | -0.41% |
| Normalized Diluted EPS | 44.84% | 44.02% | 44.36% | -2.90% | 4.39% |
| Average Basic Shares Outstanding | -2.33% | -2.03% | 144.90% | 145.64% | 146.35% |
| Average Diluted Shares Outstanding | -2.62% | -2.33% | 144.49% | 145.20% | 145.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |